Burcon increases convertible debenture private placement to $6.9 million

Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) announced it has increased the size of its non-brokered private placement of convertible debentures to an aggregate principal amount of up to $6.9 million, citing strong investor demand.

The Vancouver-based plant-based protein technology company previously announced the private placement on January 2, 2026. Insiders and the company's manufacturing partner owners have committed to participating for a minimum of $5.0 million in principal amount.

"We are encouraged by the strong investor interest in a challenging market," said Kip Underwood, Burcon's chief executive officer. The company reaffirmed its revenue target of more than $10 million for calendar 2026.

The private placement has received conditional approval from the Toronto Stock Exchange, subject to compliance with approval terms including receipt of disinterested shareholder approval.

Burcon develops plant-based protein ingredients for the food and beverage industry, with a patent portfolio covering proteins derived from pea, canola, soy, hemp, sunflower, and other plant sources. The company has operated for over two decades in the plant-based protein sector.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Cantor Fitzgerald Upgrades Capricor Therapeutics (CAPR) to Overweight
• BMO Capital Resumes Snowline Gold Corp (SGD:CN) (SNWGF) at Outperform